Subtopic Deep Dive
Targeted Therapies in Cholangiocarcinoma
Research Guide
What is Targeted Therapies in Cholangiocarcinoma?
Targeted therapies in cholangiocarcinoma use molecular inhibitors against FGFR fusions, IDH1 mutations, HER2 amplifications, and immunotherapy to treat advanced bile duct cancers.
FGFR inhibitors like BGJ398 target fusions in 10-15% of intrahepatic cholangiocarcinoma cases (Goyal et al., 2016). IDH inhibitors and HER2 agents address specific genetic aberrations identified in molecular profiling (Ross et al., 2014). Over 10 papers from 2008-2021 detail resistance mechanisms and trial outcomes, with NCCN guidelines recommending these for advanced disease (Benson et al., 2021).
Why It Matters
Targeted therapies improve response rates in FGFR fusion-positive cholangiocarcinoma, achieving 18.8% objective response with BGJ398 before resistance via polyclonal FGFR2 mutations emerges (Goyal et al., 2016). NCCN guidelines integrate these agents for second-line treatment post-chemotherapy, extending progression-free survival in biomarker-selected patients (Benson et al., 2021). Molecular subtyping reveals proliferation and inflammation classes guiding therapy selection (Sia et al., 2013). Next-generation sequencing identifies actionable targets like FGFR and HER2 in 20-40% of cases, shifting from gemcitabine-cisplatin alone (Ross et al., 2014).
Key Research Challenges
Acquired FGFR Inhibitor Resistance
Polyclonal secondary FGFR2 mutations drive resistance to BGJ398 in fusion-positive cholangiocarcinoma patients (Goyal et al., 2016). Sequential biopsy analysis shows multiple resistant clones emerging post-treatment. Combination strategies or next-generation inhibitors are under evaluation.
Biomarker Identification Variability
Next-generation sequencing reveals heterogeneous targets like FGFR, IDH1, and HER2, but low prevalence limits trial accrual (Ross et al., 2014). Intrahepatic subtypes show distinct molecular classes with differing outcomes (Sia et al., 2013). Standardized profiling remains inconsistent across centers.
Limited Systemic Options
Advanced cholangiocarcinoma lacks curative therapies beyond chemotherapy, with targeted agents confined to small subsets (Bañales et al., 2020). NCCN guidelines note poor prognosis despite FGFR/IDH approvals (Benson et al., 2021). Inflammation-driven progression complicates immunotherapy responses (Landskron et al., 2014).
Essential Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca et al. · 2020 · Nature Reviews Gastroenterology & Hepatology · 2.3K citations
Chronic Inflammation and Cytokines in the Tumor Microenvironment
Glauben Landskron, Marjorie De la Fuente, Peti Thuwajit et al. · 2014 · Journal of Immunology Research · 1.7K citations
Acute inflammation is a response to an alteration induced by a pathogen or a physical or chemical insult, which functions to eliminate the source of the damage and restore homeostasis to the affect...
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesús M. Bañales, Vincenzo Cardinale, Guido Carpino et al. · 2016 · Nature Reviews Gastroenterology & Hepatology · 1.3K citations
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott et al. · 2021 · Journal of the National Comprehensive Cancer Network · 987 citations
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile duc...
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Supriya K. Saha, Andrew X. Zhu, Charles S. Fuchs et al. · 2016 · The Oncologist · 774 citations
Abstract Background. Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy. Methods. We ana...
Cholangiocarcinoma
Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas et al. · 2021 · Nature Reviews Disease Primers · 768 citations
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has distinct genetic abe...
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?
Tadahiro Takada, Hodaka Amano, Hideki Yasuda et al. · 2002 · Cancer · 628 citations
Abstract BACKGROUND To the authors' knowledge, the significance of postoperative adjuvant chemotherapy in pancreaticobiliary carcinoma has not yet been clarified. A randomized controlled study eval...
Reading Guide
Foundational Papers
Start with Ross et al. (2014) for NGS-discovered targets like FGFR in ICC, then Goyal et al. (2016) for resistance mechanisms; Blechacz & Gores (2008) provides CCA basics.
Recent Advances
Bañales et al. (2020) for therapy horizons; Benson et al. (2021) NCCN guidelines; Brindley et al. (2021) for subtype-specific aberrations.
Core Methods
Next-generation sequencing for mutations (Ross et al., 2014), molecular class discovery via integrative analysis (Sia et al., 2013), resistance sequencing from patient biopsies (Goyal et al., 2016).
How PapersFlow Helps You Research Targeted Therapies in Cholangiocarcinoma
Discover & Search
Research Agent uses searchPapers('FGFR inhibitors cholangiocarcinoma') to retrieve Goyal et al. (2016) on resistance mutations, then citationGraph to map 525 citing papers on next-gen inhibitors, and findSimilarPapers to uncover related HER2 trials from Ross et al. (2014). exaSearch semantic query 'IDH1 targeted therapy intrahepatic cholangiocarcinoma' surfaces NCCN updates (Benson et al., 2021).
Analyze & Verify
Analysis Agent applies readPaperContent on Goyal et al. (2016) to extract resistance mutation frequencies, verifyResponse with CoVe against raw abstracts for 100% alignment, and runPythonAnalysis to plot response rates from trial data using pandas/matplotlib. GRADE grading scores FGFR inhibitor evidence as high-quality based on phase II metrics.
Synthesize & Write
Synthesis Agent detects gaps in FGFR combination trials post-Goyal et al. (2016), flags contradictions between inflammation roles (Landskron et al., 2014) and targeted efficacy. Writing Agent uses latexEditText for therapy comparison tables, latexSyncCitations with Bañales et al. (2020), latexCompile for manuscripts, and exportMermaid for resistance pathway diagrams.
Use Cases
"Extract survival data from FGFR inhibitor trials in cholangiocarcinoma and plot Kaplan-Meier curves"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Goyal et al. 2016) → runPythonAnalysis(pandas survival analysis, matplotlib plots) → researcher gets CSV-exported curves with statistical p-values.
"Draft LaTeX review section on targeted therapies citing NCCN and Bañales papers"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft text) → latexSyncCitations(Benson et al. 2021, Bañales et al. 2020) → latexCompile(PDF) → researcher gets compiled section with synced references.
"Find GitHub repos analyzing cholangiocarcinoma sequencing data from Ross 2014 paper"
Research Agent → paperExtractUrls(Ross et al. 2014) → paperFindGithubRepo → githubRepoInspect → researcher gets repo links with FGFR mutation analysis code and NGS pipelines.
Automated Workflows
Deep Research workflow runs searchPapers on 'cholangiocarcinoma targeted therapies' yielding 50+ papers including Goyal et al. (2016), then DeepScan with 7-step CoVe checkpoints analyzes resistance mechanisms step-by-step. Theorizer generates hypotheses on FGFR-IDH combinations from Bañales et al. (2020) and Ross et al. (2014), outputting Mermaid diagrams of proposed trials.
Frequently Asked Questions
What defines targeted therapies in cholangiocarcinoma?
Agents targeting FGFR fusions (BGJ398), IDH1 mutations, HER2 amplifications via sequencing-identified alterations in 20-40% of cases (Ross et al., 2014; Goyal et al., 2016).
What are key methods in these therapies?
Next-generation sequencing for target ID (Ross et al., 2014), FGFR inhibition with resistance monitoring via serial biopsies (Goyal et al., 2016), NCCN-recommended biomarker testing (Benson et al., 2021).
What are major papers?
Goyal et al. (2016, 525 citations) on FGFR resistance; Ross et al. (2014, 454 citations) on NGS targets; Bañales et al. (2020, 2290 citations) on management horizons.
What open problems exist?
Overcoming polyclonal FGFR2 resistance (Goyal et al., 2016), expanding targets beyond 40% of patients (Ross et al., 2014), validating combinations in phase III trials (Benson et al., 2021).
Research Cholangiocarcinoma and Gallbladder Cancer Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Targeted Therapies in Cholangiocarcinoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers